Join us this March for the first ever CURE Patient-Focused Sessions, taking place at the Miami Breast Cancer Conference! 

×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Ovarian Cancer

Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
The Foundation for Women’s Cancer Continues the Fight to End Gynecologic Cancer One Step at a Time; Race Set for Nov. 4, 2018 in Washington, DC
Kristie L. Kahl
In this week’s episode, we speak with author and avid patient advocate Shannon Pulaski about her new efforts to help empower children to learn about their family’s health history.
Brielle Urciuoli
In recent years, treatment has expanded for mutations that are well-understood in this space.
Kristie L. Kahl
A recent survey of physicians revealed that 17 percent of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Brielle Urciuoli
According to a recent study conducted at the University of Alabama at Birmingham Schools of Public Health and Medicine, disparities among patients who receive instructions for this follow-up care still exist.
Khevin Barnes
Through correspondence with TV personality Fred Rogers, one survivor of cancer found hope and inspiration.
Brielle Urciuoli
In recent decades, researchers have gained a much better understanding of how gynecologic cancers develop, especially for women who carry genetic mutations.
 
Brielle Urciuoli
A common goal for palliative care is pain management, where opioids like morphine are often on the frontline. Then, practitioners may build on medications from there, adding agents such as gabapentin and tricyclic antidepressants. But if those don’t work, Christopher J. Pietras, M.D. said that ketamine may be an option.
 
Kristie L. Kahl
The combination use of Tumor Treating Fields plus paclitaxel more than doubled progression-free survival, with no serious treatment-related side effects in women with recurrent, platinum-resistant ovarian cancer.
Ursula A. Matulonis, M.D.
Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other